Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06855160 · ClinicalTrials.gov registry record · Phase 3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

A Phase 3 study of Chickenpox, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 3
Development phase
900
Enrollment target
12
Study locations

NCT06855160 is a Phase 3 study of Chickenpox that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 900 participants, above the 667-participant average among 4 other Chickenpox trials with a reported enrollment target (35% higher). The trial reports 12 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06855160, a Phase 3 study of Chickenpox, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 3
Development phase
900 participants
Enrollment target
12
Study locations

Study Summary

This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.

Conditions Studied

Chickenpox

Interventions

  • BIOLOGICAL Candidate varicella vaccine
  • BIOLOGICAL Marketed varicella vaccine
  • BIOLOGICAL MMR vaccine
  • BIOLOGICAL Hepatitis A vaccine
  • BIOLOGICAL PCV (pneumococcal conjugate vaccine) 13

Study Locations (12)

Florida

  • GSK Investigational Site - Coral Gables
  • GSK Investigational Site - Miami Lakes
  • GSK Investigational Site - Tampa

Texas

  • GSK Investigational Site - Houston
  • GSK Investigational Site - Lewisville
  • GSK Investigational Site - Pharr

California

  • GSK Investigational Site - Huntington Park
  • GSK Investigational Site - Sherman Oaks

Arizona

  • GSK Investigational Site - Tucson

Idaho

  • GSK Investigational Site - Idaho Falls

Ohio

  • GSK Investigational Site - Dayton

Other

  • GSK Investigational Site - Alken

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2025-04-17
Est. Completion 2027-02-02
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06855160

The ClinicalTrials.gov registry entry for NCT06855160 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 667-participant average among 4 other Chickenpox trials with a reported enrollment target (35% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chickenpox appearing as the primary indexed condition, and to 5 interventions - of which Candidate varicella vaccine is the first listed.

NCT06855160 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Florida, Texas, California.

Frequently Asked Questions

What is clinical trial NCT06855160 about?

NCT06855160 is a clinical study titled "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age". This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study...

What is the current status of trial NCT06855160?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2025-04-17. Estimated completion is 2027-02-02.

What conditions does trial NCT06855160 study?

This clinical trial studies the following conditions: Chickenpox.

What interventions are being tested in trial NCT06855160?

The interventions under investigation include: Candidate varicella vaccine (BIOLOGICAL), Marketed varicella vaccine (BIOLOGICAL), MMR vaccine (BIOLOGICAL), Hepatitis A vaccine (BIOLOGICAL), PCV (pneumococcal conjugate vaccine) 13 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06855160?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06855160 being conducted?

This trial has 12 study locations across Arizona, California, Florida, Idaho, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chickenpox

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chickenpox

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.